Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $200 to $220.
Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $200 to $220.